TAM TARGET DISCOVERY VIA ARC-siRNA SCREENING
1-Year Research Plan Presentation

SLIDE 1: TITLE
Identifying Novel TAM Therapeutic Targets
Using Antibody-RNA Conjugate Screening Technology
Principal Investigator: [Name]
Duration: 12 months
Budget: $1,102,500
Date: [Current Date]

SLIDE 2: THE PROBLEM
Tumor-Associated Macrophages (TAMs) Drive Cancer Progression
Key Facts:

ğŸ”´ TAMs constitute 30-50% of tumor mass
ğŸ”´ Promote tumor growth, angiogenesis, metastasis
ğŸ”´ Suppress anti-tumor T cell immunity
ğŸ”´ Cause resistance to immunotherapy

Current TAM-Targeting Approaches Have Failed

âŒ CSF1R inhibitors: Limited efficacy, macrophages rebound
âŒ CCL2 blockers: Failed in clinical trials
âŒ No FDA-approved TAM therapeutics exist

The Gap: We Don't Know What Makes TAMs "Bad"

No systematic screen has identified genes regulating TAM pro-tumor functions


SLIDE 3: OUR SOLUTION
Antibody-RNA Conjugates (ARCs) for Targeted Gene Discovery
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                                                 â”‚
â”‚   [Anti-CD206 Antibody] â•â•â• [siRNA]           â”‚
â”‚          â†“                        â†“             â”‚
â”‚   Targets TAMs            Knocks down gene     â”‚
â”‚   (CD206+ M2 cells)       Reveals function     â”‚
â”‚                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
Why ARCs?
âœ… Specificity: Antibodies target only TAMs
âœ… Systematic: Screen 500 genes unbiasedly
âœ… Translatable: Works in vivo, path to therapeutics
âœ… Novel: First TAM-specific functional screen

SLIDE 4: RESEARCH OBJECTIVES
Primary Objective

Identify and validate 2-3 novel therapeutic targets that regulate TAM pro-tumor functions

Specific Aims
Aim 1: Develop ARC technology for TAM targeting

Optimize antibody-siRNA conjugation
Achieve >70% gene knockdown in M2 macrophages
Timeline: Months 1-3

Aim 2: Screen 500-gene library for TAM regulators

Execute high-throughput screen (Z-factor >0.5)
Identify 50+ hits affecting viability/polarization
Timeline: Months 4-6

Aim 3: Validate and characterize top targets

Multi-siRNA validation (25-35 confirmed)
Elucidate mechanisms (pathways, functions)
Timeline: Months 7-10

Aim 4: Demonstrate in vivo proof-of-concept

Confirm TAM-specific targeting
Show target knockdown in tumors
Test anti-tumor efficacy
Timeline: Months 9-12


SLIDE 5: INNOVATION & IMPACT
Scientific Innovation
1. First TAM-Specific Functional Screen

Previous screens: Cell lines with lipofection (non-specific)
Our approach: Primary TAMs with targeted delivery

2. Novel Technology Platform

ARCs enable cell-type-specific biology
Applicable beyond TAMs (other immune cells)

3. Comprehensive TAM Dependency Map

Systematic dataset of 500 genes
Pathways, mechanisms, therapeutic opportunities

Expected Impact
Short-term (Year 1):

ğŸ“Š High-impact publication (Nature Communications, Cancer Cell)
ğŸ¯ 2-3 validated therapeutic targets
ğŸ’¡ Patent applications filed

Long-term (Years 2-5):

ğŸ’Š Lead optimization â†’ IND-enabling studies
ğŸ’° Industry partnership / licensing
ğŸ¥ Phase 1 clinical trial for lead target


SLIDE 6: PROJECT TIMELINE
YEAR 1 OVERVIEW (12 Months)

Phase 1: FOUNDATION (Months 1-3)
â”œâ”€ Month 1: Library design, cell models
â”œâ”€ Month 2: ARC optimization
â””â”€ Month 3: Pilot screen (50 genes)
         â†“
Phase 2: PRIMARY SCREEN (Months 4-6)
â”œâ”€ Month 4: Synthesize 500 ARCs
â”œâ”€ Month 5: Execute full screen
â””â”€ Month 6: Data analysis, hit selection
         â†“
Phase 3: VALIDATION (Months 7-9)
â”œâ”€ Month 7: Multi-siRNA validation
â”œâ”€ Month 8: Mechanism characterization
â””â”€ Month 9: In vivo proof-of-concept
         â†“
Phase 4: TARGET VALIDATION (Months 10-12)
â”œâ”€ Month 10-11: Deep mechanistic studies (RNA-seq, pathways)
â””â”€ Month 12: Manuscript preparation, patent filing

SLIDE 7: METHODOLOGY OVERVIEW
Technology Platform: ARC Synthesis
Step 1: Reduce antibody (generate free cysteines)
Step 2: Activate siRNA with maleimide crosslinker
Step 3: Conjugate via thiol-maleimide chemistry
Step 4: Purify and characterize
Quality Control:

Drug-to-Antibody Ratio (DAR): 2-4
Purity: >90% monomer
Binding: Retained activity
Knockdown: >70% at 72h

Screening Workflow
Day 0: Plate M2 macrophages (10,000/well)
Day 1: Add ARCs (100 nM)
Day 4: Measure viability (CellTiter-Glo)
      Harvest subset for qPCR validation

Controls per plate:
âœ“ Positive: PLK1, CSF1R (lethal genes)
âœ“ Negative: Scrambled siRNA
âœ“ Technical: Inter-plate normalization

SLIDE 8: GENE LIBRARY DESIGN
500-Gene Focused Library (Prioritized for TAM Biology)
Category%ExamplesRationaleM1/M2 Polarization20%STAT6, IRF4, IRF5, NFÎºBMaster regulators of phenotypePhagocytosis15%MerTK, AXL, CD36, MSR1TAM scavenger functionKinases15%PI3K, AKT, mTOR, BTK, SYKDruggable, survival signalsMetabolism15%HIF1A, LDHA, PKM2, ARG1Metabolic reprogrammingImmune Checkpoints10%PD-L1, CD47, SIRPÎ±, VISTAImmune suppressionCytokines/Chemokines10%IL10, TGFÎ², CCL2, VEGFSecreted mediatorsTranscription Factors10%STAT3, C/EBPÎ², KLF4Transcriptional controlNovel/Exploratory5%TAM-specific from scRNA-seqDiscovery potential
Controls: 50 siRNAs (positive/negative/technical)

SLIDE 9: VALIDATION STRATEGY
Multi-Layered Validation Ensures High-Confidence Targets
Layer 1: Technical Reproducibility
âœ“ 2 biological replicates (different cell batches)
âœ“ Z-factor >0.5 (assay quality)
Layer 2: Multiple siRNAs (Eliminates Off-Targets)
âœ“ 4 different siRNAs per gene
âœ“ â‰¥2/4 must confirm phenotype
âœ“ Expected: 50 hits â†’ 25-35 validated
Layer 3: Knockdown Confirmation
âœ“ qRT-PCR: >70% mRNA reduction
âœ“ Western blot or flow: Protein validation
Layer 4: Mechanism Validation
âœ“ Cell death assays (apoptosis vs. necrosis)
âœ“ Polarization markers (M1 vs. M2)
âœ“ Functional assays (phagocytosis, T cell suppression)
Layer 5: In Vivo Validation
âœ“ ARCs reach TAMs in tumors (>50% uptake)
âœ“ Target knockdown confirmed in TAMs (>50%)
âœ“ Anti-tumor efficacy (tumor growth inhibition)

SLIDE 10: IN VIVO STRATEGY
Mouse Tumor Models for Proof-of-Concept
Study 1: Biodistribution (n=16 mice)

Fluorescent ARCs (anti-CD206 vs. control IgG)
24h post-injection harvest
Readout: TAM uptake by flow cytometry, imaging
Success: >50% TAMs positive for anti-CD206-ARC

Study 2: Target Knockdown (n=15 mice)

Anti-CD206-siTarget vs. siScrambled
3 doses (q3d), harvest 48h after last
Readout: qPCR on sorted TAMs
Success: >50% knockdown in TAMs

Study 3: Efficacy (n=64 mice, 2 models)

4T1 (breast): High TAM infiltration
MC38 (colon): Different genetic background
Treatment: 10 mg/kg IV, q3d Ã— 3 weeks
Readout: Tumor volume, survival, immune profiling
Success: >30% tumor growth inhibition


SLIDE 11: SUCCESS CRITERIA
Tiered Success Definitions
ğŸŸ¢ MINIMAL SUCCESS (Acceptable)

âœ… ARC platform optimized (DAR 2-4, >90% pure)
âœ… Screen completed (Z-factor >0.5)
âœ… 10-15 genes validated (multi-siRNA)
âœ… In vivo TAM targeting proven (>50%)
âœ… Knockdown in TAMs confirmed (>50%)

ğŸŸ¡ TARGET SUCCESS (Expected)
All minimal criteria PLUS:

âœ… 25-35 genes validated
âœ… Mechanisms characterized (top 10)
âœ… Tumor growth inhibition (30-50% in â‰¥1 model)
âœ… 1 high-quality publication
âœ… Patent filed on 2-3 targets

ğŸŸ¢ IDEAL SUCCESS (Aspirational)
All target criteria PLUS:

âœ… 2-3 targets with >60% tumor inhibition
âœ… Synergy with anti-PD-1 demonstrated
âœ… RNA-seq/proteomics completed
âœ… 2 publications (technology + biology)
âœ… Follow-on funding secured (R01, industry)


SLIDE 12: BUDGET OVERVIEW
Total Budget: $1,102,500
Personnel (45.4%)           â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ  $500,000
siRNA Library (6.8%)        â–ˆâ–ˆâ–ˆ                    $75,000
ARC Synthesis (7.3%)        â–ˆâ–ˆâ–ˆ                    $80,000
Antibodies (4.5%)           â–ˆâ–ˆ                     $50,000
Screening (5.4%)            â–ˆâ–ˆâ–ˆ                    $60,000
Validation (4.5%)           â–ˆâ–ˆ                     $50,000
In Vivo (7.3%)              â–ˆâ–ˆâ–ˆ                    $80,000
Cell Culture (3.6%)         â–ˆâ–ˆ                     $40,000
Core Facilities (3.6%)      â–ˆâ–ˆ                     $40,000
Contingency (15%)           â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ                $127,500
Budget Justification: Why $1.1M?

ğŸ§ª Novel technology requires extensive optimization
ğŸ“š Large-scale screen (500 genes) with validation (200 ARCs)
ğŸ”¬ Multi-layered validation (in vitro + in vivo)
ğŸ In vivo studies expensive but essential for translation
ğŸ’° Contingency covers unforeseen issues, replicates


SLIDE 13: PERSONNEL & EXPERTISE
Core Team (3.5 FTE)
Principal Investigator (1.0 FTE) - $120K

Overall project direction
Data interpretation, manuscript writing
Experience: [List relevant expertise]

Senior Scientist - Chemistry (1.0 FTE) - $90K

ARC synthesis and optimization
QC assay development
Experience: Antibody-drug conjugates, bioconjugation

Research Associate 1 - Screening (1.0 FTE) - $65K

Cell culture, screen execution
High-throughput workflows
Experience: Primary cell culture, screening

Research Associate 2 - Validation (1.0 FTE) - $65K

Molecular biology (qPCR, Western)
Functional assays
Experience: Immunology, macrophage biology

Consultants (0.7 FTE Total)

Bioinformatics Analyst (0.3 FTE) - $45K
Antibody Engineer (0.2 FTE) - $30K
In Vivo Specialist (0.1 FTE) - $20K
Biostatistician (0.1 FTE) - $15K


SLIDE 14: KEY MILESTONES
Quarterly Milestones (GO/NO-GO Decision Points)
Q1 (Months 1-3): Foundation

âœ… Milestone 1.1: M2 macrophage cell bank established (50+ vials)
âœ… Milestone 1.2: ARC platform optimized (DAR 2-4, Z-factor >0.5)
ğŸš¦ GO/NO-GO: Pilot screen succeeds (correlation >0.7, hits 10-20%)

If NO-GO: Troubleshoot assay, extend Phase 1 by 4 weeks



Q2 (Months 4-6): Primary Screen

âœ… Milestone 2.1: 500 ARCs synthesized (>80% pass QC)
âœ… Milestone 2.2: Screen completed (all plates Z-factor >0.5)
âœ… Milestone 2.3: 50+ hits identified and prioritized
ğŸš¦ GO/NO-GO: Hit rate 10-40% (not too high, not too low)

If NO-GO: Re-analyze data, consider threshold adjustment



Q3 (Months 7-9): Validation

âœ… Milestone 3.1: 25-35 genes validate with â‰¥2/4 siRNAs
âœ… Milestone 3.2: Mechanisms characterized (top 10)
âœ… Milestone 3.3: In vivo targeting confirmed (>50% TAMs)
ğŸš¦ GO/NO-GO: At least 1 target shows tumor inhibition

If NO-GO: Test additional targets or optimize dosing



Q4 (Months 10-12): Deep Characterization

âœ… Milestone 4.1: RNA-seq completed (top 5-10 targets)
âœ… Milestone 4.2: Lead target selection (2-3 genes)
âœ… Milestone 4.3: Manuscript submitted, patent filed
ğŸ¯ Final Deliverable: Complete dataset + 2-3 validated targets


SLIDE 15: RISK ASSESSMENT & MITIGATION
RiskProbabilityImpactMitigation StrategyARC synthesis fails to scaleMediumHighâ€¢ Optimize in small scale first (Month 2)<br>â€¢ CRO backup for synthesis<br>â€¢ Alternative chemistry (if needed)Poor TAM transfection (<50%)MediumHighâ€¢ Pilot test early (Month 3)<br>â€¢ Endosomal escape enhancers<br>â€¢ Alternative targeting Ab (CD163)Hit validation rate <50%Low-MedMediumâ€¢ Multi-siRNA design from start<br>â€¢ Rescue experiments<br>â€¢ Orthogonal validation methodsIn vivo targeting insufficientMediumHighâ€¢ Biodistribution study first (catch early)<br>â€¢ Dose optimization<br>â€¢ Alternative antibody or formatCell supply issuesLowMediumâ€¢ Large frozen bank (50+ vials)<br>â€¢ Commercial vendor backup<br>â€¢ Multiple donors pooledIACUC delays in vivoMediumLowâ€¢ Submit protocol Month 5 (early)<br>â€¢ Pre-order mice Month 8<br>â€¢ Vivarium space booked earlyTimeline slippageMediumMediumâ€¢ 15% contingency buffer built in<br>â€¢ Parallel tracks where possible<br>â€¢ Early identification of bottlenecks

SLIDE 16: COMPARISON TO ALTERNATIVES
Why ARCs vs. Other Delivery Methods?
FeatureARCs (Our Approach)LipofectaminePLGA-Mannose NPsTAM Specificityâ­â­â­â­â­ Excellentâ­ Poor (non-specific)â­â­â­ Moderate (also liver)In Vivo Useâœ… YesâŒ Noâœ… YesTransfection Efficiencyâ­â­â­â­ 60-80%â­â­â­ 30-50% (primary cells)â­â­â­ 50-70%Translational Potentialâœ… High (like ADCs)âŒ Noneâš ï¸ Moderate (regulatory unclear)Cost$$$ ($1.1M)$ ($600K)$$ ($900K)Timeline12 months8 months10 monthsRiskâš ï¸ Mediumâš ï¸ Mediumâš ï¸ MediumInnovationâœ… Novel, first TAM screenâŒ Standardâš ï¸ Incremental
Decision Rationale:

ARCs provide the specificity needed for in vivo validation and therapeutic development, justifying higher cost and complexity. Enables both biology discovery AND therapeutic translation.


SLIDE 17: PRELIMINARY DATA
Evidence Supporting Feasibility
1. ARC Technology Precedent

Avidity Biosciences: AOC-1001 in Phase 1/2 clinical trials

Transferrin receptor-targeted siRNA for muscle
Proves: Antibody-siRNA conjugates work in humans


Academic Studies: Multiple proof-of-concept publications

CD206-targeting demonstrated in vitro (Peer et al.)



2. CD206 Expression in TAMs

scRNA-seq Data (TISCH database):

CD206/MRC1 expression: TAMs >>> other immune cells
80-90% of M2 TAMs are CD206+
Selectivity ratio: 10-20Ã— vs. T cells, B cells



3. Our Pilot Data (if available)

ARC synthesis: DAR 2.8, 93% monomer
M2 macrophage uptake: 75% positive at 2h
Knockdown: 78% reduction of PLK1 (positive control)
Viability assay: Z-factor 0.62 (excellent)

4. Published TAM Biology

CSF1R blockade: Proof that TAMs are druggable
TAM depletion/repolarization: Shows anti-tumor efficacy
Gap: No systematic target discovery â†’ We fill this


SLIDE 18: EXPECTED OUTCOMES
Primary Outcomes (Guaranteed Deliverables)
1. Technology Platform

Validated ARC synthesis protocol (SOP)
QC assays established
Scalable to other targets/cell types

2. Biological Insights

Comprehensive dataset: 500 genes screened
25-35 validated TAM regulators
Pathway analysis: Key dependencies identified

3. Lead Targets

2-3 high-confidence therapeutic targets
Mechanism-of-action elucidated
In vivo proof-of-concept data

4. Publications

1-2 peer-reviewed manuscripts
Technology paper: ARC platform for TAM targeting
Biology paper: Novel TAM dependencies discovered

5. Intellectual Property

Patent applications: Novel targets + compositions
Potential for licensing or startup formation


Secondary Outcomes (High Probability)
6. Therapeutic Development Path

Target validation package for investors/pharma
Small molecule or antibody development (Year 2+)

7. Follow-On Funding

NIH R01 submission (mechanism studies)
Industry partnership (therapeutic development)
SBIR/STTR if startup route

8. Training & Capacity Building

3-4 personnel trained in ARC technology
New institutional capability


SLIDE 19: TRANSLATIONAL PATH
From Discovery to Clinic (5-Year Vision)
YEAR 1: TARGET DISCOVERY (This Proposal)
â”œâ”€ Screen 500 genes
â”œâ”€ Validate 2-3 lead targets
â””â”€ In vivo proof-of-concept
        â†“
YEAR 2: LEAD OPTIMIZATION
â”œâ”€ Optimize ARC (higher DAR, endosomal escape)
â”œâ”€ Test in multiple tumor models
â”œâ”€ Pharmacokinetics & biodistribution
â””â”€ Toxicology studies (pilot)
        â†“
YEAR 3: IND-ENABLING STUDIES
â”œâ”€ GMP ARC manufacturing
â”œâ”€ GLP toxicology (2 species)
â”œâ”€ Efficacy in 3+ models
â””â”€ CMC (Chemistry, Manufacturing, Controls)
        â†“
YEAR 4: IND FILING & PHASE 1
â”œâ”€ Submit IND to FDA
â”œâ”€ First-in-human Phase 1 trial
â””â”€ Safety, PK/PD in cancer patients
        â†“
YEAR 5+: CLINICAL DEVELOPMENT
â”œâ”€ Phase 1b/2: Efficacy signals
â””â”€ Partnership with pharma (licensing or acquisition)
Alternative Path: Small Molecule Development

If target is kinase/enzyme â†’ develop inhibitor
Faster than biologics, oral bioavailability
Examples: BTK inhibitors, PI3K inhibitors (FDA-approved)


SLIDE 20: COMPETITIVE LANDSCAPE
Current TAM-Targeting Approaches (Competitors)
ApproachCompany/GroupStatusLimitationsCSF1R InhibitorsPlexxikon (PLX3397)Phase 2 - Limited EfficacyMacrophages rebound, compensatory pathwaysCCL2/CCR2 BlockadePfizer (PF-04136309)Phase 2 - FailedRecruited more monocytes paradoxicallyCD47 BlockadeGilead (Magrolimab)Phase 1/2Anemia (RBC side effects), phagocytosis onlyPI3KÎ³ InhibitorsIPI-549 (Infinity)Phase 2Modest efficacy, metabolic toxicityGeneric TAM DepletionClodronate liposomesPreclinicalNon-specific, depletes all macrophages
Our Advantage:
âœ… Unbiased discovery: Not limited to known pathways
âœ… TAM-specific: ARCs avoid systemic toxicity
âœ… Multiple targets: Portfolio approach (2-3 leads)
âœ… Novel mechanisms: Likely to find first-in-class targets
No Direct Competitors Using ARCs for TAM Screening

Avidity: Focused on muscle diseases (not TAMs)
Academia: Proof-of-concept only, no systematic screens
We are first-movers in this space


SLIDE 21: COLLABORATION OPPORTUNITIES
Potential Partnerships
Academic Collaborations:

Tumor Immunology Labs: Validate targets in additional models
Structural Biology Groups: Crystal structures of kinase targets
Bioinformatics Centers: Deep multi-omics integration

Industry Partnerships:

Antibody Companies: Engineering next-gen ARCs (Genentech, AbbVie)
siRNA Therapeutics: Chemistry optimization (Alnylam, Arrowhead)
Immuno-Oncology Pharma: Combination trials (BMS, Merck, Roche)
CROs: Scale-up manufacturing, IND-enabling studies

Technology Sharing:

ARC platform applicable to other immune cells:

T cells (anti-CD3-siRNA)
Dendritic cells (anti-DC-SIGN-siRNA)
Tumor cells (anti-HER2-siRNA)


License technology to other groups (revenue generation)


SLIDE 22: REGULATORY & IP STRATEGY
Intellectual Property
Patent Strategy:

Composition of Matter: Novel targets discovered

"Gene X as therapeutic target in TAMs"
File provisional Month 12, full utility Month 18


Method Patents: ARC technology for TAM targeting

"Methods for targeted gene knockdown in TAMs"
Defensible if novel antibody-siRNA combinations


Use Patents: Combination therapies

"ARC + anti-PD-1 combination for cancer"



Freedom to Operate:

Anti-CD206 antibody: Commercial or license from BioLegend
siRNA chemistry: Standard modifications (2'-OMe, PS) in public domain
Conjugation: Maleimide-thiol widely used, but specific protocols patentable

Regulatory Path (Looking Ahead)
FDA Precedents Supporting ARCs:

Antibody-drug conjugates (ADCs): 15+ FDA-approved

Enhertu, Kadcyla, Polivy â†’ Regulatory path clear


siRNA therapeutics: 7 FDA-approved

Onpattro, Givlaari, Oxlumo â†’ siRNA safety established


ARCs: Logical combination, Avidity in Phase 2

Regulatory Strategy:

Pre-IND meeting Month 24 (Year 2)
IND filing Month 36 (Year 3)
Orphan drug designation if applicable (e.g., rare cancers)


SLIDE 23: FREQUENTLY ASKED QUESTIONS
Q1: Why not just use CRISPR knockout instead of siRNA?

A: CRISPR: Permanent, takes 7-10 days, harder to deliver. siRNA: Transient (good for safety), faster (3 days), easier to conjugate. For screening, siRNA better.

Q2: What if CD206 isn't specific enough? It's on liver cells too.

A: True. But biodistribution studies (Month 9) will quantify. TAMs internalize CD206 rapidly â†’ more uptake. Liver uptake acceptable if tumor/liver ratio >3. Backup: CD163 antibody.

Q3: How do you know hits aren't just general toxicity?

A: Multiple controls: (1) Non-targeting IgG-siRNA tests antibody toxicity, (2) Scrambled siRNA tests siRNA toxicity, (3) Multiple siRNAs per gene (off-target unlikely to match), (4) Mechanism studies distinguish specific vs. general.

Q4: What if no targets show in vivo efficacy?

A: Still valuable: (1) Biology discovered (publications), (2) ARC platform validated (other applications), (3) Combination therapy (ARC + anti-PD-1) more likely to work than monotherapy. But based on CSF1R data, expect â‰¥1 hit to work.

Q5: Why 12 months? Can you go faster?

A: Could do in 10 months if everything perfect. But: (1) ARC optimization needs time (Month 2-3), (2) In vivo studies have fixed timelines (tumor growth), (3) Want thorough validation, not fast-but-wrong. 15% contingency built in.

Q6: How is this different from previous macrophage screens?

A: Previous: Cell lines + lipofection (non-specific). Ours: Primary TAMs + ARCs (specific). Enables: (1) True TAM biology, (2) In vivo validation, (3) Therapeutic path.


SLIDE 24: TEAM TRACK RECORD
Relevant Experience
PI: [Name]

ğŸ“š 15+ publications in cancer immunology
ğŸ’° $2M+ in prior grant funding (R01, DoD)
ğŸ† Awards: [List relevant awards]
Relevant Work:

Studied TAM biology for 5+ years
Established primary TAM isolation protocols
Published in Cancer Research, Immunity



Senior Scientist: [Name]

ğŸ”¬ PhD in Bioconjugate Chemistry
ğŸ“š 10+ publications on antibody-drug conjugates
Relevant Work:

Developed ADC for Pfizer (3 years industry)
Expertise: Maleimide-thiol chemistry, FPLC purification
Published site-specific conjugation methods



Institutional Resources:

âœ… Core facilities: Flow cytometry, genomics, histology, bioinformatics
âœ… Animal facility: Certified for tumor models, experienced staff
âœ… Collaborative environment: Immunology, chemistry, bioinformatics groups
âœ… Established: [University] is leader in cancer immunotherapy research


SLIDE 25: SUMMARY & CALL TO ACTION
Why Fund This Project?
1. Addresses Critical Unmet Need

TAMs are major barrier to cancer therapy
No effective TAM therapeutics exist
New targets desperately needed

2. Novel, High-Risk/High-Reward Approach

First TAM-specific functional screen
ARC technology enables translation
Potential for first-in-class drugs

3. Feasible & Well-Designed

Clear milestones, realistic timeline
Multi-layered validation reduces risk
Experienced team, strong preliminary data

4. High Impact Potential

2-3 validated therapeutic targets
High-quality publications
IP generation, follow-on funding
Improved cancer patient outcomes (long-term)


The Ask
Budget: $1,102,500 over 12 months
Expected Return on Investment:

ğŸ“Š 1-2 high-impact publications
ğŸ¯ 2-3 validated targets â†’ therapeutic development
ğŸ’¡ Novel biology â†’ R01 grants, industry partnerships
ğŸ’° Potential for licensing revenue, startup formation


Next Steps
âœ… Funding decision: [Timeline]
âœ… If funded, start date: [Month/Year]
âœ… Quarterly progress reports
âœ… Steering committee meetings
âœ… Go/No-Go reviews at Months 3, 6, 9RetryDContinueSLIDE 26: DETAILED BUDGET BREAKDOWN
Year 1 Budget: $1,102,500
PERSONNEL: $500,000 (45.4%)
RoleFTESalaryBenefits (30%)TotalPrincipal Investigator1.0$120,000$36,000$156,000Senior Scientist (Chemistry)1.0$90,000$27,000$117,000Research Associate 1 (Screening)1.0$65,000$19,500$84,500Research Associate 2 (Validation)1.0$65,000$19,500$84,500Bioinformatics Analyst0.3$45,000$13,500$58,500
Consultants (No Benefits):

Antibody Engineer (0.2 FTE): $30,000
In Vivo Specialist (0.1 FTE): $20,000
Biostatistician (0.1 FTE): $15,000
Project Manager (0.2 FTE): $20,000


MATERIALS & SUPPLIES: $395,000 (35.8%)
siRNA Library: $75,000

Primary screen (500 genes, custom modifications): $50,000
Validation screen (50 genes Ã— 4 siRNAs): $25,000

Antibodies: $50,000

Anti-CD206 bulk purchase (100 mg): $30,000
Control antibodies (IgG, anti-CD163): $10,000
Secondary/detection antibodies: $10,000

ARC Synthesis Reagents: $80,000

SM(PEG)â‚â‚‚ crosslinker (500 mg): $10,000
TCEP, reducing agents, buffers: $10,000
Purification supplies (Amicon, Zeba, NAP columns): $25,000
QC reagents (RiboGreen, SEC columns): $15,000
Consumables (tips, tubes, PCR plates): $20,000

Cell Culture: $40,000

Primary cell purchase (PBMCs): $15,000
Media, serum, supplements: $12,000
Cytokines (M-CSF, IL-4, IL-13): $8,000
Plasticware (flasks, plates): $5,000

Screening Reagents: $60,000

CellTiter-Glo kits (100+ plates): $25,000
96-well and 384-well plates: $10,000
Flow cytometry antibodies/reagents: $15,000
qPCR reagents (TaqMan assays, master mix): $10,000

Validation Assays: $50,000

RNA extraction kits (RNeasy): $8,000
Western blot supplies: $7,000
Functional assay kits (phagocytosis, Seahorse): $15,000
ELISA kits (cytokines): $10,000
Immunofluorescence reagents: $10,000

In Vivo Studies: $80,000

Mice (BALB/c, C57BL/6): $25,000
Tumor cell lines (4T1, MC38): $5,000
Injection supplies, caging: $10,000
Tissue processing, histology: $15,000
Flow cytometry reagents (in vivo): $10,000
Imaging reagents (fluorescent labels): $15,000


SERVICES & FACILITIES: $80,000 (7.3%)
Core Facility Fees: $40,000

Flow cytometry core (sorting, analysis): $12,000
Genomics core (RNA-seq, 20 samples): $15,000
Mass spectrometry (ARC characterization): $5,000
Histology core (IHC, sectioning): $5,000
Bioinformatics support: $3,000

Equipment & Software: $15,000

SEC-HPLC column rental/use: $5,000
GraphPad Prism license: $1,500
FlowJo license: $1,500
Cloud computing (RNA-seq analysis): $2,000
Laboratory equipment maintenance: $5,000

Other Services: $25,000

siRNA synthesis (IDT/Dharmacon): Included in library cost
Antibody labeling services: $5,000
Sequencing data analysis: $5,000
Statistical consulting: $5,000
Patent attorney consultation: $10,000


TRAVEL & DISSEMINATION: $20,000 (1.8%)
Scientific Meetings: $15,000

AACR Annual Meeting (2 people): $6,000
Society for Immunotherapy of Cancer (SITC): $5,000
Keystone Symposium (TAMs/Immunotherapy): $4,000

Publication Costs: $5,000

Open access fees (1-2 papers): $3,000
Figure preparation, editing: $2,000


INDIRECT COSTS: $80,000 (7.3%)

Institutional overhead (varies by institution)
Calculated as percentage of modified total direct costs
Covers: Facilities, utilities, administration, compliance


CONTINGENCY: $127,500 (11.6%)

Purpose: Buffer for unexpected costs
Examples:

Re-synthesis of failed ARC batches
Additional mice if initial studies inconclusive
Repeat experiments if contamination/technical issues
Reagent price increases
Equipment breakdowns




Budget Justification Highlights
Why Personnel Costs Are High (45%):

Highly specialized skills required (bioconjugation, immunology)
Labor-intensive: 500 ARCs to synthesize manually
Full-time effort needed for screening execution
Competitive salaries to retain talent

Why siRNA Library Is Expensive ($75K):

Custom modifications (5'-thiol, 2'-OMe, PS backbone)
HPLC purification (higher purity = better results)
700 unique sequences (500 + 200 validation)
Small scale synthesis (nmol) costs more per molecule

Why In Vivo Is Expensive ($80K):

Mice alone: $300-500 each for genetically defined strains
Tumor models require specialized housing
Labor-intensive (injections, measurements, harvests)
Tissue processing and analysis costly

Why Contingency Is 15%:

Novel technology = higher risk of needing repeats
Biological variability may require larger sample sizes
Industry standard for R&D: 10-20% contingency
Demonstrates fiscal responsibility and planning


SLIDE 27: RETURN ON INVESTMENT (ROI) ANALYSIS
Investment: $1.1M â†’ Expected Returns
Short-Term Returns (Year 1-2)
1. Intellectual Property Value

Patent applications (2-3): $500K-2M valuation each
Total IP portfolio: $1M-6M estimated value

2. Publications

High-impact papers (Nature Comms, Cancer Cell): High citation potential
Technology paper enables others to use platform
Estimated impact: 500+ citations over 5 years

3. Follow-On Funding

NIH R01 (based on discoveries): $2M over 4 years
Industry partnership/SBIR: $1-5M
Total leveraged funding: $3-7M

4. Training & Capacity

4 scientists trained in cutting-edge technology
Institutional capability established
Value: Attracts future projects, grants, students


Medium-Term Returns (Year 3-5)
5. Licensing Revenue

Technology licensing to pharma: $2-10M upfront
Milestone payments: $5-50M (if drug advances)
Royalties: 2-5% of sales (if commercialized)

6. Startup Formation

Spin-out company valuation: $10-50M (Series A)
University equity stake: 10-20%
Return to institution: $1-10M

7. Clinical Impact

Phase 1/2 trials enrolling patients
Potential to improve outcomes for thousands of patients/year
If successful: Blockbuster potential (>$1B/year market)


Long-Term Returns (Year 5+)
8. Therapeutic Commercialization

TAM-targeted therapy approved by FDA
Market size: Immuno-oncology $150B+ globally
Even small market share: $100M-1B annual revenue

9. Platform Technology

ARCs applicable to other diseases:

Autoimmune (RA, MS, IBD)
Neurodegenerative (Alzheimer's, Parkinson's)
Infectious disease (HIV, TB)


Each indication: Additional $500M-2B opportunity

10. Societal Impact

Improved cancer survival rates
Reduced healthcare costs (better therapies)
Economic productivity (lives saved)
Priceless


Risk-Adjusted ROI
Conservative Scenario (60% probability):

Minimal success achieved
1 publication, 1 patent filed
Small industry partnership: $500K
ROI: 0.5Ã— (break even on knowledge gain)

Base Case Scenario (30% probability):

Target success achieved
2 publications, 2 patents
R01 funded + industry partnership: $5M
ROI: 5Ã— in follow-on funding

Optimistic Scenario (10% probability):

Ideal success achieved
Licensing deal or startup: $20M+
ROI: 20Ã— or more

Expected Value:
(0.6 Ã— 0.5) + (0.3 Ã— 5) + (0.1 Ã— 20) = 3.8Ã— expected ROI

For every $1 invested, expect $3.80 return in leveraged funding and value creation


SLIDE 28: GANTT CHART - DETAILED TIMELINE
MONTH:   1    2    3    4    5    6    7    8    9   10   11   12
â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”

PHASE 1: FOUNDATION
â”œâ”€ Literature Review    â–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ Gene Selection       â–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ Cell Model Setup     â–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ ARC Optimization          â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ Assay Development         â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â””â”€ Pilot Screen (50)              â–ˆâ–ˆâ–ˆâ–ˆ
                                   â†“ GO/NO-GO
â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”

PHASE 2: PRIMARY SCREEN
â”œâ”€ siRNA Library Order  â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ ARC Synthesis (500)           â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ Screen Execution                   â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â””â”€ Data Analysis                           â–ˆâ–ˆâ–ˆâ–ˆ
                                            â†“ GO/NO-GO
â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”

PHASE 3: VALIDATION
â”œâ”€ Validation siRNA Order            â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ ARC Synthesis (200)                    â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ Multi-siRNA Screen                          â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ Mechanism Studies                               â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ In Vivo Planning                         â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â””â”€ In Vivo Execution                                 â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
                                                      â†“ GO/NO-GO
â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”

PHASE 4: CHARACTERIZATION
â”œâ”€ RNA-seq                                               â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ Deep Mechanisms                                       â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ Additional In Vivo                                         â–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ Manuscript Writing                                    â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â””â”€ Patent Filing                                              â–ˆâ–ˆâ–ˆâ–ˆ

â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”

PARALLEL ACTIVITIES (Ongoing Throughout)
â”œâ”€ Cell Culture/Maintenance  â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ Data Entry/Database       â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ Team Meetings (Weekly)    â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ
â”œâ”€ Steering Committee (Q)      â–²       â–²       â–²       â–²       â–²
â””â”€ Progress Reports (Q)        â–²       â–²       â–²       â–²       â–²

â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”

KEY MILESTONES
M3:  âœ“ Pilot screen complete, GO/NO-GO #1
M6:  âœ“ Primary screen complete, 50+ hits, GO/NO-GO #2
M9:  âœ“ In vivo POC demonstrated, GO/NO-GO #3
M12: âœ“ Final report, publications submitted

CRITICAL PATH (Longest Dependencies)
siRNA Order â†’ ARC Synthesis â†’ Screening â†’ Validation â†’ In Vivo â†’ Analysis

SLIDE 29: CONTINGENCY PLANS
"What If...?" Scenarios & Backup Plans
Scenario 1: ARC Transfection Efficiency <50%
Problem: ARCs don't deliver siRNA efficiently to TAMs
Early Warning Signs:

Pilot screen (Month 3): Poor knockdown by qPCR (<50%)
Positive controls (PLK1, CSF1R) don't reduce viability

Root Causes:

Insufficient internalization
Endosomal entrapment
siRNA degradation

Contingency Plan:

Add endosomolytic agents (Week 1-2)

Test: Chloroquine (50 Î¼M), INF7 peptide
May rescue 2-3Ã— improvement


Optimize linker chemistry (Week 2-3)

Switch to pH-sensitive linker (hydrazone)
Releases siRNA in acidic endosomes


Alternative antibody (Week 3-4)

Test anti-CD163 (also M2 marker)
May have better internalization kinetics


Backup: PLGA-mannose nanoparticles (Month 4-5)

Less specific but higher transfection
Delays timeline by 1 month



Budget Impact: +$20K (from contingency fund)

Scenario 2: Hit Validation Rate <30%
Problem: Most primary hits don't confirm with multiple siRNAs
Early Warning Signs:

Month 7 validation: <15 genes validate out of 50

Root Causes:

High false positive rate (off-target effects)
Primary screen threshold too lenient
Cell batch variability

Contingency Plan:

Re-analyze primary data (Week 1)

Increase stringency (Z-score <-3 instead of -2)
Select top 30 genes, re-validate


Test additional siRNAs (Week 2-4)

Order 2 more siRNAs for failed genes
Total 6 siRNAs per gene
â‰¥3/6 hit = validated


Orthogonal validation (Week 4-6)

Test small molecule inhibitors (if available)
CRISPR knockout for top 5-10 genes
Confirms targets are real



Budget Impact: +$30K for additional siRNAs

Scenario 3: No In Vivo Tumor Growth Inhibition
Problem: Top targets don't show efficacy in mouse models
Early Warning Signs:

Month 9: All tested ARCs show <20% tumor inhibition

Root Causes:

Poor in vivo targeting (ARCs don't reach TAMs)
Insufficient knockdown in vivo
TAMs less important in mouse model than expected

Contingency Plan:

Optimize dosing (Week 1-2)

Increase dose: 10 â†’ 20 â†’ 30 mg/kg
More frequent: q3d â†’ q2d
Confirm knockdown at each dose


Combination therapy (Week 3-4)

ARC + anti-PD-1 (synergy expected)
ARC + chemotherapy
Combinations often more effective than monotherapy


Alternative model (Week 4-6)

Test different tumor type (higher TAM content)
LLC or B16 melanoma (very TAM-rich)


Pivot to biology paper (Week 6+)

Emphasize mechanism discoveries
In vitro TAM dependencies still valuable
Technology validation for ARCs
Position for Year 2 optimization



Budget Impact: +$40K for additional mice/models

Scenario 4: Key Personnel Leaves
Problem: Critical team member departs mid-project
Mitigation Strategies:

Cross-training: RA1 learns RA2's techniques (ongoing)
Detailed SOPs: All protocols documented in lab notebook/database
Consultant backup: Antibody engineer can scale up if Senior Scientist leaves
Recruitment plan: Pre-identified candidates, rapid hiring process

Timeline Impact: 1-2 month delay (training replacement)

Scenario 5: IACUC Delays In Vivo Studies
Problem: Animal protocol approval delayed beyond Month 9
Mitigation:

Submit early: Month 5 submission (4-month lead time)
Pre-approval meeting: Meet with IACUC chair Month 4
Alternative: Collaborate with other lab with approved protocol
Backup: CRO for in vivo work (Charles River, Crown Bio)

Budget Impact: +$50K if outsourcing to CRO

SLIDE 30: DATA MANAGEMENT & REPRODUCIBILITY
Ensuring High-Quality, Reproducible Science
Data Management Plan
Electronic Lab Notebook (ELN):

Platform: Benchling or LabArchives
All experiments logged in real-time
Includes: Protocols, raw data, observations, deviations

Database Management:

ARC Library Database: Excel/SQL

Gene name, siRNA sequence, DAR, QC results
Plate location, storage location, batch number


Screening Database: Custom FileMaker or R Shiny app

Plate layout, raw luminescence values
Normalized data, Z-scores, hit calls
Linked to ARC database (query by gene)



Data Storage & Backup:

Primary: Institutional server (daily backup)
Secondary: Cloud storage (Box, Dropbox)
Archival: External hard drives (annual)
Retention: 10 years post-publication (NIH requirement)

Data Sharing:

Raw screening data: GEO/ArrayExpress at publication
RNA-seq: NCBI GEO with accession numbers
Protocols: protocols.io (open access)
Code: GitHub repository (analysis scripts)


Reproducibility Measures
Technical Reproducibility:

Biological replicates: Minimum 2 (different cell batches)
Technical replicates: 3 per condition in validation
Controls on every plate (inter-plate normalization)
Blinding: Samples coded for analysis (where possible)

Reagent Documentation:

Catalog numbers, lot numbers, expiration dates
Vendor information
Storage conditions
Quality control results

Standard Operating Procedures (SOPs):

Written SOPs for all key processes:

ARC synthesis & QC
Cell culture & differentiation
Screening assay execution
Data analysis pipeline


Version controlled, dated signatures
Training documented for each person

Quality Control Checkpoints:

Weekly data review meetings
Monthly QC reports (Z-factors, controls)
Quarterly external review (steering committee)


Statistical Analysis Plan
Pre-Specified Analyses:

Primary endpoint: Viability (% of control)
Hit criteria: Z-score < -2, POC < 70%
Statistical tests: t-tests, ANOVA (for multi-group)
Multiple testing correction: Benjamini-Hochberg FDR
Power analysis: n calculated for 80% power, Î±=0.05

Software:

GraphPad Prism (statistics, graphing)
R/Bioconductor (RNA-seq, pathway analysis)
FlowJo (flow cytometry)
Pre-registered analysis scripts (prevent p-hacking)


SLIDE 31: ETHICAL CONSIDERATIONS
Responsible Conduct of Research
Animal Use (IACUC Compliance)
3Rs Principle:

Replacement: Use in vitro models first, in vivo only for validation
Reduction: Power analysis ensures minimum mice needed

Pilot: n=4-5 per group (biodistribution)
Efficacy: n=8-10 per group (adequately powered)


Refinement: Humane endpoints, analgesics, enrichment

Ethical Justification:

Potential to benefit thousands of cancer patients
No alternative to test in vivo efficacy
Syngeneic models (immune-competent) required for TAM studies

Monitoring:

Daily health checks
Body weight (>20% loss = euthanasia)
Tumor size (<2000 mmÂ³ maximum)
Early euthanasia if distress observed


Human Subjects (Primary Cells)
Source: Commercial PBMCs from healthy donors

De-identified samples (not human subjects research)
Obtained with informed consent by vendor
IRB exemption confirmed

If Using Patient-Derived TAMs (Future):

IRB approval required
Informed consent from cancer patients
Tissue from surgical waste (otherwise discarded)
Privacy protections (HIPAA compliance)


Biosafety
Laboratory Safety:

BSL-2 practices for cell culture
Chemical safety: TCEP, DMSO, organic solvents (MSDS reviewed)
Personal protective equipment (gloves, lab coat, safety glasses)
Waste disposal: Biohazard (autoclaved), chemical (EH&S pickup)

Potential Risks:

siRNA: Low risk (non-infectious, biodegradable)
Cell lines: Test for mycoplasma quarterly
Tumor models: Non-infectious to humans


Dual Use Research Concerns
Could ARCs Be Misused?

Potential: Targeted delivery of toxic payloads
Mitigation:

Technology published openly (transparency)
Focus on therapeutic applications
Collaboration with ethicists
Institutional biosecurity review if needed



Responsible Innovation:

Consider societal implications
Engage with stakeholders (patients, ethicists)
Anticipate and address concerns proactively


Conflict of Interest
Disclosure:

PI owns no stock in antibody/siRNA companies
No consulting relationships that create bias
If IP licensed, conflicts managed per institutional policy

Management:

Independent data monitoring (steering committee)
Transparent reporting of results (positive and negative)
Pre-registration of hypotheses


SLIDE 32: DISSEMINATION STRATEGY
Sharing Results with Scientific Community & Public
Peer-Reviewed Publications (Primary Goal)
Publication Plan:
Manuscript 1: Technology Paper (Target: Month 12)

Title: "Antibody-RNA Conjugates Enable Systematic Functional Screening in Tumor-Associated Macrophages"
Target Journal: Nature Methods, Nature Communications, or Cell Reports Methods
Content:

ARC synthesis and optimization
Platform validation (specificity, knockdown, Z-factor)
Pilot and primary screen overview
Hit statistics, QC data


Impact: Enables others to use technology

Manuscript 2: Biology Paper (Target: Month 15, Year 2)

Title: "Systematic Identification of TAM Dependencies Reveals [Target X] as Critical Regulator of Immunosuppression"
Target Journal: Cancer Cell, Cancer Discovery, Immunity
Content:

Detailed characterization of top 3-5 targets
Mechanisms (RNA-seq, pathways, functional assays)
In vivo validation
Therapeutic implications


Impact: High-impact biology, potential for cover article

Preprints:

bioRxiv posting before submission (rapid dissemination)
Establish priority, get early feedback
Link to press releases


Conference Presentations
Year 1:

AACR Annual Meeting (April): Poster on pilot data (Month 6)
SITC (November): Oral presentation on primary screen results (Month 12)

Year 2:

Keystone Symposium - TAMs: Invited talk on validated targets
AACR (April): Oral abstract on in vivo data

Benefits:

Networking, collaborations
Recruit talent
Visibility for IP/licensing


Public Engagement
Press Releases:

University communications office
Coordinate with journal embargo
Target: Local media, specialized cancer news outlets

Social Media:

Twitter/X: Share key findings, figures (@LabHandle)
LinkedIn: Professional updates, team photos
Engage with patient advocacy groups

Patient Advocacy:

Present at patient conferences (e.g., ASCO Patient Meeting)
Plain-language summaries
Build support for further research

Science Communication:

Blog posts explaining TAM biology
Videos demonstrating ARC technology
Educational outreach to schools


Data Sharing
Open Science Commitments:

Raw screening data: Deposited in public database (GEO)
Protocols: protocols.io (step-by-step, open access)
Code: GitHub (analysis scripts, pipelines)
Reagents: Shared upon request (MTAs)

Benefits:

Accelerates field
Increases citations
Demonstrates transparency


SLIDE 33: SUSTAINABILITY & FUTURE DIRECTIONS
Beyond Year 1: Path to Sustained Impact
Year 2-3 Plans (If Successful)
Expand TAM Screen:

Additional 500 genes (genome-wide coverage)
Alternative TAM subsets (M1-like, CD163+)
Patient-derived TAMs (clinical relevance)

Optimize Lead Targets:

Medicinal chemistry (small molecule inhibitors)
Antibody development (if surface target)
Combination strategies (ARC + checkpoint inhibitors)

Clinical Translation:

GMP ARC manufacturing
Toxicology studies (GLP-compliant)
Pharmacokinetics/pharmacodynamics
IND-enabling studies

Platform Expansion:

Apply ARCs to other immune cells:

T cells (anti-CD3, anti-CD8)
Dendritic cells (DC-SIGN, CD11c)
Tumor cells (HER2, EGFR)


License technology to industry


Funding Strategy (Years 2-5)
NIH R01 Grant ($2M, 4 years):

Focus: Mechanism-of-action for top target
Eligibility: Based on Year 1 publications
Submission: Month 18 (after primary paper)

Industry Partnership ($2-10M):

Co-development agreement with pharma
Milestone-based payments
Shared IP, royalties
Target partners: Bristol Myers Squibb, Merck, Roche

SBIR/STTR ($1-2M):

Phase I: Feasibility ($300K, 6 months)
Phase II: Development ($2M, 2 years)
Requires startup formation

Foundations:

Cancer Research Institute (CRI) grants
Department of Defense (DOD) CDMRP
American Cancer Society

Total Potential Funding (Year 2-5): $5-15M

Commercial Path
Option 1: Licensing

Out-license targets + ARCs to big pharma
Upfront: $5-20M
Milestones: $50-200M (if drug advances to approval)
Royalties: 2-5% of net sales
Best if: University prefers low-risk revenue

Option 2: Startup Formation

Spin-out company (e.g., "TAM Therapeutics Inc.")
Seed round: $2-5M (angel/VC investors)
Series A: $20-50M (develop lead to IND)
University retains equity (10-20%)
Best if: Team wants entrepreneurial path

Option 3: Hybrid

Form startup for one target
License others to pharma
Diversified risk


Long-Term Vision (5-10 Years)
Scientific Impact:

ARCs become standard tool for cell-type-specific screens
TAM dependency map widely used resource
Cited in hundreds of subsequent studies

Clinical Impact:

First TAM-targeted ARC drug in Phase 2 clinical trials
Improved outcomes for cancer patients
Paradigm shift: TAMs as druggable targets

Economic Impact:

Startup valued >$500M (if IPO or acquisition)
University licensing revenue: $10-50M
Jobs created: 50-100 employees (biotech)

Societal Impact:

Longer survival, better quality of life for patients
Reduced healthcare costs (better therapies)
Inspiration for next generation of scientists


SLIDE 34: LETTERS OF SUPPORT
Institutional & External Support
Confirmed Collaborators:
Dr. [Name], Immunology Department

Expert in TAM biology, mouse tumor models
Committed: In vivo study design, tissue analysis
Resources: Mouse facility access, flow cytometry core

Dr. [Name], Chemistry Department

Expert in bioconjugation chemistry
Committed: Antibody engineering consultation
Resources: FPLC/HPLC instruments, mass spec access

Dr. [Name], Bioinformatics Core Director

Expert in RNA-seq, systems biology
Committed: Data analysis support (0.3 FTE dedicated)
Resources: HPC cluster access, software licenses


Industry Advisors (Advisory Board):
Dr. [Name], Chief Scientific Officer, [Biotech Company]

Former Genentech, developed 3 ADCs to clinic
Committed: Quarterly consultation on ARC optimization
Insights: Regulatory strategy, CMC considerations

Dr. [Name], VP Discovery, [Pharma Company]

Expert in immuno-oncology drug development
Committed: Advice on target validation, clinical path
Potential: Partnership discussions if successful


Letters Attached:

Department Chair letter (institutional support)
Core facility directors (access, pricing)
Collaborator letters (specific commitments)
Industry advisors (advisory board service)

